EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
Explore this paper's citation graph
Summary
ddPCR is more sensitive in plama ctDNA testing and should be performed even in tumor tissue T790M test negative cases, and EGFR T790m mutation level is not associated with clinical response after osimertinib treatment.
- Type
- article
- Published
- 2018-08-13
- Cited by
- 19
- References
- 18
- Access
- Open access
- OpenAlex
- https://openalex.org/W2887887720
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:51975997
Keywords
Osimertinib, T790M, Liquid biopsy, Acquired resistance, Adenocarcinoma
References
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
- New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
- Global cancer statistics
- Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
- Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline
- Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
- Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer
- Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
- Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas® EGFR mutation test.
- Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
- P2.03-040 EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
- Global cancer statistics, 2012
Cited by
- Scar tissue to lung cancer; pathways and treatment
- Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
- EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
- Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay
- Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis
- Extracellular genetic materials and their application in clinical practice.
- A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic
- Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
- Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
- The efficacy of T790M mutation testing in liquid biopsy—Real clinic data
- Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
- Electrochemiluminescent CdS Quantum Dots Biosensor for Cancer Mutation Detection at Different Positions on Linear DNA Analytes.
- The diagnostic performance of dual-layer spectral detector CT for distinguishing breast cancer biomarker expression and molecular subtypes
- Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing
- Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer
- Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGS
- Observational Study of Re-Biopsy in EGFR-TKI-Resistant Patients with EGFR Mutation-Positive Advanced NSCLC
- miRNAs in the Era of Personalized Medicine: From Biomarkers to Therapeutics
Related papers
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
- 19P Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation
- Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
- 57P Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma
- Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
- Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
- Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review
- ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) - European subset.
- EP1.14-10 Investigation of Mechanisms of Acquired Resistance to Afatinib with Plasma DNA in Non-Small Cell Lung Cancer Patients